The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 6 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: Cognitive dysfunction is often present in major depressive disorder (MDD). Several clinical trials have noted a pro-cognitive effect of antidepressants in MDD. The objective of the current systematic review and meta-analysis was to assess the pooled efficacy of antidepressants on various domains of cognition in MDD. METHODS: Trials published prior to April 15, 2015, were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Data from randomized clinical trials assessing the cognitive effects of antidepressants were pooled to determine standard mean differences (SMD) using a random-effects model. RESULTS: Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified. Antidepressants had a positive effect on psychomotor speed (SMD 0.16; 95% confidence interval [CI] 0.05-0.27; I(2) = 46%) and delayed recall (SMD 0.24; 95% CI 0.15-0.34; I(2) = 0%). The effect on cognitive control and executive function did not reach statistical significance. Of note, after removal of vortioxetine from the analysis, statistical significance was lost for psychomotor speed. Eight head-to-head randomized trials comparing the effects of selective serotonin reuptake inhibitors (SSRIs; n = 371), selective serotonin and norepinephrine reuptake inhibitors (SNRIs; n = 25), tricyclic antidepressants (TCAs; n = 138), and norepinephrine and dopamine reuptake inhibitors (NDRIs; n = 46) were identified. No statistically significant difference in cognitive effects was found when pooling results from head-to-head trials of SSRIs, SNRIs, TCAs, and NDRIs. Significant limitations were the heterogeneity of results, limited number of studies, and small sample sizes. CONCLUSIONS: Available evidence suggests that antidepressants have a significant positive effect on psychomotor speed and delayed recall.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found that antidepressants have small, statistically significant positive effects on psychomotor speed and delayed recall in major depressive disorder, but not on cognitive control or executive function. Head-to-head trials showed no statistically significant differences between antidepressant classes, and the psychomotor speed effect lost significance after removing vortioxetine.
Key findings
- In nine placebo-controlled randomized trials (2,550 participants), antidepressants improved psychomotor speed (SMD 0.16; 95% CI 0.05–0.27; I² = 46%) and delayed recall (SMD 0.24; 95% CI 0.15–0.34; I² = 0%). Effects on cognitive control (SMD 0.10; 95% CI −0.06 to 0.26; p = 0.21) and executive function (SMD 0.12; 95% CI −0.03 to 0.28; p = 0.12) were not statistically significant.
- Vortioxetine had the largest pooled effect size (0.34; 95% CI 0.17–0.50; p = 0.0001), followed by duloxetine (0.10; 95% CI −0.01 to 0.22). After removing vortioxetine, the psychomotor speed effect was no longer significant (SMD 0.08; 95% CI −0.02 to 0.18; p = 0.13).
- In head-to-head trials, no statistically significant difference was found between SSRIs/SNRIs and TCAs on pooled memory domains (SMD 0.33; 95% CI −0.11 to 0.78; p = 0.14), or between SSRIs and NDRIs on working memory (SMD −0.22; 95% CI −0.62 to 0.19). Sertraline outperformed fluoxetine on psychomotor speed (SMD 0.38; 95% CI 0.11–0.66; p = 0.006).
- A subgroup analysis found a greater positive effect in subjects younger than 65 (SMD 0.23; 95% CI 0.04–0.43; p = 0.02) than in those older than 65 (SMD 0.10; 95% CI 0.00–0.21; p = 0.06), but the difference between subgroups was not statistically significant (p = 0.24).
Methods
- Systematic review and meta-analysis of randomized clinical trials published before April 15, 2015, identified through Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Inclusion required adults over 18 with MDD, antidepressant monotherapy with monoamine modulation, and cognition assessed by standardized validated measures.
- Data were pooled using standard mean differences (SMD) with a random-effects model in Review Manager 5.3. Placebo-controlled trials compared final cognitive scores of antidepressant versus placebo; head-to-head trials compared one antidepressant with another. Risk of bias was assessed across five domains, and a funnel plot was created for psychomotor speed.
- Searches yielded 1,084 articles plus 23 from reference lists; 45 full texts were reviewed, 25 studies were included qualitatively, and 17 were included quantitatively. Nine placebo-controlled trials and eight head-to-head trials contributed to the meta-analysis.
Limitations
- The paper states that high heterogeneity of cognitive testing limited comparison and pooling, that moderate heterogeneity was present in pooled SMDs, that the number of studies and sample sizes were small, and that vortioxetine and duloxetine were heavily weighted; removing vortioxetine eliminated statistical significance for psychomotor speed.
- The paper also states that many included studies had potential for-profit bias due to pharmaceutical company funding, and that the functional meaning of the small cognitive test improvements remains largely unknown.
- Evident from the text: an Egger test could not be performed because fewer than ten studies were available, funnel plot interpretation was limited, most studies evaluated cognition as a secondary outcome, and responder/non-responder subgroup analyses were not possible due to insufficient reporting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









![Figure 10. Pooled effect on psychomotor speed (Digit Symbol Sign Test [DSST]) for sertraline versus fluoxetine. CI, confidence interval; SD, standard definition.](https://figures.cochat.ai/paper-figures/30fee3d872fd45778bc9237ce37a68a7/the-cognitive-effects-of-antidepressants-in-major-depressive-disorder-a-figure-10.jpg)
Verification
Claims the paper makes
5 Valid · 2 Not valid · 3 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several cognitive domains, including executive function, attention, memory, processing speed, and psychomotor skills, are affected during both symptomatic as well as “remitted” phases in MDD (Marazziti et al., 2010; Lee et al., 2012; Bora et al., 2013; Bortolato et al., 2014).”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Introduction
What the sources say
- Not checked — no full text of the sourcecites Marazziti et al., 2010 source
- Not checked — no full text of the sourcecites Lee et al., 2012 source
- Partly supportedcites Bora et al., 2013 sourceExperimental — accuracy not yet measured
The Cognitive domains results (page not provided) report poorer performance in euthymic MDD patients across the domains studied, including executive function, attention, memory, and processing speed. The Introduction says cognitive functions are often impaired in MDD, but this meta-analysis does not establish that every listed domain is affected during symptomatic phases; the Discussion addresses psychomotor inhibitory control specifically, not psychomotor skills broadly. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, since the publication of their review, several new clinical trials have been published that have primarily sought to determine the effects of antidepressants on cognitive function (Katona et al., 2012; McIntyre et al., 2014; Robinson et al., 2014; Soczynska et al., 2014; Gorlyn et al., 2015; Mahableshwarkar et al., 2015).”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Introduction
What the sources say
- Not checked — no full text of the sourcecites Katona et al., 2012 source
- Supportedcites McIntyre et al., 2014 source
The Discussion identifies this as a large randomized study in adults with major depressive disorder whose pre-defined primary clinical outcome was cognitive performance. It therefore supports citing McIntyre et al. (2014) as one of the trials primarily designed to test an antidepressant’s effects on cognition. (LLM, conf=0.94)
- Not matchedcites Robinson et al., 2014
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pooled effect size of both antidepressants (n = 989) versus placebo (n = 616) was 0.24 (95% CI 0.15 to 0.34; p < 0.00001), indicative of a small, yet statistically significant, positive effect”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Pooled Effect Sizes for Placebo-Controlled Trials
hedgedstates a causen = 989 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The SMD of all antidepressants (n = 984) versus placebo (n = 494) was 0.12 (95% CI -0.03 to 0.28; p = 0.12) is shown in Figure 6, indicative of a non–statistically significant effect.”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Pooled Effect Sizes for Placebo-Controlled Trials
hedgedn = 984- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified.”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Abstract > Results:
plainn = 2,550- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 46 claims and every source verdict.
- It may state two separate claims as one. 9
- Probably not a substantial claim. 5
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, a significant proportion of MDD patients continue to experience significant cognitive impairment.”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“A recent meta-analysis further indicates that standard antidepressant drugs may ameliorate certain cognitive domains in patients with MDD, namely psychomotor speed and delayed recall [20].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [20]
In the citing paper
“Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has been demonstrated to have procognitive effects compared to placebo.65”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [65]
In the citing paper
“However, the evidence base remains limited, and the effect sizes derived from this meta-analysis were small in magnitude (standard mean difference was 0.16 for psychomotor speed and 0.24 for delayed recall, respectively).”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Search Results and Study Characteristics
“Of the articles included in the quantitative review, nine were placebo-controlled randomized trials, with four trials evaluating two antidepressants compared to the same placebo group and the remaining evaluating a single antidepressant compared to placebo.”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Pooled Effect Sizes for Placebo-Controlled Trials
“In total, nine placebo-controlled studies evaluated psychomotor speed using DSST or a combined speed measure (Georgotas et al., 1989; Ferguson et al., 2003; Raskin et al., 2007; Hoffman et al., 2008; Culang et al., 2009; Katona et al., 2012; McIntyre et al., 2014; Robinson et al., 2014; Mahableshwarkar et al., 2015). Of these studies, three studies evaluated two agents in parallel compared to placebo”
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
A compendium of neuropsychological tests: administration, norms, and commentary
(1991) · Choice Reviews Online · doi:10.5860/choice.29-2400 · Cited by 6,120
Strauss, E., & Spreen, O. (2009) · Cited by 1,444
Kessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.9.1561 · Cited by 868 · cited 1×
“2 | International Journal of Neuropsychopharmacology, 2016 Introduction Major depressive disorder (MDD) is a highly prevalent and disabling illness affecting greater than 350 million people worldwide (Kessler et al., 2006).”
BackgroundKessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1561 · Cited by 868
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationA meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737
Cognitive impairment in euthymic major depressive disorder: a meta-analysis
Bora, E., Harrison, B. J., Yücel, M., & Pantelis, C. (2013) · Psychological Medicine · doi:10.1017/s0033291712002085 · Cited by 551 · cited 18×
“Due to the known persistence of cognitive dysfunction during remission (Bora et al., 2013) and demonstrated small positive effect of antidepressants on delayed recall and psychomotor speed, the investigation of other cognitively enhancing agents to be used adjunctively to current antidepressants…”
BackgroundInfluentialCognitive impairment in major depression
Marazziti, D., Consoli, G., Picchetti, M., Carlini, M., & Faravelli, L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.046 · Cited by 448
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · cited 4×
“Of these studies, one study (Katona et al., 2012) evaluated two agents in parallel compared to placebo, providing a total of five Ta b le 1 .”
BackgroundMethodInfluential
Cited by
Items 201–300 of 317
Belfiori, M., Salis, F., Demelas, G., & Mandas, A. (2024) · Brain Sciences · doi:10.3390/brainsci14010054 · Cited by 6
Leonhardi, J., Barthel, H., Speerforck, S., Dietzel, J., Schroeter, M. L., Saur, D., Tiepolt, S., Rullmann, M., Patt, M., Claßen, J., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215619 · Cited by 7
Social cognition in bipolar I and II disorders: an updated systematic review and meta-analysis
Zhang, B., Chen, X., & Qiu, N. (2025) · BMC Psychiatry · doi:10.1186/s12888-024-06462-z · Cited by 9
Liu, C., Li, L., Pan, W., Zhu, D., Lian, S., Liu, Y., Ren, L., Mao, P., Ren, Y., & Ma, X. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1107320 · Cited by 10
Malik, M., Khan, M. U., Hussain, A., & Hashmi, A. (2019) · Archives of Psychiatry and Mental Health · doi:10.29328/journal.apmh.1001006 · Cited by 8
Laursen, B., Bundgaard, C. H., Graversen, C., Grupe, M., Sánchez, C., Leiser, S. C., Sørensen, H. B. D., Drewes, A. M., & Bastlund, J. F. (2017) · Brain Research · doi:10.1016/j.brainres.2017.03.024 · Cited by 6
Response trajectories during escitalopram treatment of patients with major depressive disorder
Nuñez, J.-J., Liu, Y. S., Cao, B., Frey, B. N., Ho, K. T., Milev, R. V., Müller, D. J., Rotzinger, S., Soares, C. N., Taylor, V. H., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115361 · Cited by 5
Neuroenhancement: State of the Art and Future Perspectives.
Marazziti, D., Avella, M. T., Ivaldi, T., Palermo, S., Massa, L., Vecchia, A. D., Basile, L., & Mucci, F. (2021) · PubMed · doi:10.36131/cnfioritieditore20210303 · Cited by 15
How to address the placebo response in the prescription SSRIs and SNRIs in children and adolescents
Koechlin, H., Kossowsky, J., Gaab, J., & Locher, C. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1475558 · Cited by 6
Lee, J., Kim, J., Kang, H.-J., Hong, J.-P., & Kim, J. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.4.461 · Cited by 7
Gudayol‐Ferré, E., Duarte-Rosas, P., Peró, M., & Guàrdia‐Olmos, J. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001150 · Cited by 7
Hwang, D.-J., Um, H.-S., Choi, D.-H., & Cho, J. (2023) · Applied Sciences · doi:10.3390/app13137680 · Cited by 6
Singh, O. P., Avinash, P., Gautam, A., Prasad, A., & Jagawat, T. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_563_24 · Cited by 6
Anxious–depressive symptoms and sleep disturbances across the Alzheimer disease spectrum
Chai, Y., Kojori, E. S., Saykin, A. J., & Yu, M. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00416-4 · Cited by 8
Yang, K., Hsieh, W.-C., & Chou, Y.-H. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.05.029 · Cited by 5
Ma, J., Dong, P., Xiao, Y., Li, R., Pan, C., Liu, J., & Li, Y. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.08.036 · Cited by 4
Ramli, F. F., Singh, N., Villa, L. M., Waters, S., Harmer, C. J., Cowen, P. J., & Godlewska, B. R. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06857-0 · Cited by 6
Aydın, E. F., Güleç, M., Oral, E., & Daloğlu, A. G. (2024) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2024.22498 · Cited by 5
Cognitive Deficits in Major Depression
Coles, A. S., Lee, Y. L., Subramaniapillai, M., & McIntyre, R. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-58131-8.00004-5 · Cited by 6
Self-citationThe Cognitive Effects of Electroconvulsive Therapy: A Critical Review
Mosti, C. B., & Brook, M. A. (2019) · Psychiatric Annals · doi:10.3928/00485713-20190313-02 · Cited by 5
Cognitive Dysfunction in the Workplace: Focus on Depression
Lam, R. W. M., & Persad, C. C. (2019) · Integrating psychiatry and primary care · doi:10.1007/978-3-030-04266-0_7 · Cited by 4
Wang, M., Chen, W., Wang, H.-T., Liu, B., Ju, Y., Dong, Q., Lu, X., Sun, J.-R., Zhang, L., Guo, H., et al. (2024) · World Journal of Psychiatry · doi:10.5498/wjp.v14.i10.1474 · Cited by 7
Parsing the heterogeneity of depression: a data-driven subgroup derived from cognitive function
Xu, C., Tao, Y., Lin, Y., Zhu, J., Li, Z., Li, J., Wang, M., Huang, T., & Shi, C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1537331 · Cited by 8
Treatment-Resistant Depression
Cusin, C., & Peyda, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_1 · Cited by 8
Plechatá, A., Hejtmánek, L., Bednářová, M., & Fajnerová, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179081 · Cited by 3
Nafilyan, V., de Coulon, A., & Avendaño, M. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf187 · Cited by 4
Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
Vicent-Gil, M., Trujols, J., Sagués, T., Serra-Blasco, M., Navarra‐Ventura, G., Mantellini, C. L., Crivillés, S., Portella, M. J., & Cardoner, N. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-025-00552-2 · Cited by 3
Saberi, A., Ebneabbasi, A., Rahimi, S., Sarebannejad, S., Şen, Z. D., Graf, H., Walter, M., Sorg, C., Camilleri, J. A., Laird, A. R., et al. (2023) · medRxiv · doi:10.1101/2023.11.24.23298991 · Cited by 3
Çökmüş, F. P., Özkan, H. M., Dikici, D. S., Aşçıbaşı, K., Alçı, D., Altunsoy, N., Kuru, E., Yüzeren, S., & Aydemır, Ö. (2021) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2021.20148 · Cited by 4
Choi, C.-H., Lee, J. H., Lee, K. H., Hong, S.-B., Kim, S.-H., Han, J., Kim, J. W., Cho, S. C., & Kim, J.-W. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0101 · Cited by 4
Diagnostik und Therapie depressiver Störungen: 2. Teil
Novak, W., Sachs, G., & Erfurth, A. (2017) · psychopraxis neuropraxis · doi:10.1007/s00739-017-0389-3 · Cited by 3
Models of depressive pseudoamnestic disorder
Choi, J.-W., Lee, S., Motter, J. N., Kim, H., Andrews, H., Doraiswamy, P. M., Devanand, D. P., & Goldberg, T. E. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12335 · Cited by 2
Metacognition in anxious-depression is state-dependent: an observational treatment studyPreprint
Fox, C. A., Lee, C. T., Hanlon, A. K., Seow, T. X. F., Lynch, K., Harty, S., Richards, D., Palacios, J. E., O’Keane, V., Stephan, K. E., et al. (2023) · eLife · doi:10.7554/elife.87193.1 · Cited by 3
Beyond cognition and sleep: Stop the domino effect
Amin, S. N., Khashaba, A. S., Alazzam, A. Y., ALKHAWALDAH, H. M., ALBAKRI, K. A., ALMAJDOUBAH, O. A., Alabdallat, Y. J., & SEIF, A. S. A. (2023) · Journal of Experimental and Clinical Medicine · doi:10.52142/omujecm.40.1.28 · Cited by 8
Characterization of cognitive functioning in complex PTSD compared to non-complex PTSD
Schöndorf, Z.-S., Terhoeven, V., Jaehn, A., Roesch-Ely, D., Friederich, H., Nikendei, C., & Kindermann, D. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1433614 · Cited by 4
Zhao, T., Luo, J., Liu, T., Xie, K., & Tang, M. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115193 · Cited by 4
Liu, X., Yang, C., Wang, X., Wang, Z., Liao, H., Liu, H., Zhang, M., Zhang, L., & Wang, H. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1518198 · Cited by 3
Dotson, V. M., Szymkowicz, S. M., Kim, J. U., & McClintock, S. M. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0159-4 · Cited by 4
Systematic Review and Meta-Analysis of Executive Function Following Remission From Major Depression
Semkovska, M., Nikolic, J., Dølven, S., & Roth, H. N. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.09.006 · Cited by 11
Increased Odds of Cognitive Impairment in Adults with Depressive Symptoms and Antidepressant Use
Meshkat, S., Wu, M., Tassone, V. K., Janssen‐Aguilar, R., Pang, H. Y. M., Jung, H. J., Lou, W. Y. W., & Bhat, V. (2024) · Pharmacopsychiatry · doi:10.1055/a-2381-2061 · Cited by 2
Psychiatric rehabilitation and cognitive deficit for treatment-resistant depression
Cheng, C., & Jeng, J. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.02.006 · Cited by 2
An observational treatment study of metacognition in anxious-depression
Fox, C. A., Lee, C. T., Hanlon, A., Seow, T. X. F., Lynch, K., Harty, S., Richards, D., Palacios, J., O'Keane, V., Stephan, K. E., et al. (2023) · doi:10.31234/osf.io/uk7hr · Cited by 2
Yang, H., Liu, Y., Yang, C., & Lin, X. (2021) · Brain and Behavior · doi:10.1002/brb3.2360 · Cited by 2
New Antidepressant Medication: Benefits Versus Adverse Effects
Bogdán, M., Gofiţă, E., Călina, D. C., Turcu-Ştiolică, A., Docea, A. O., Bălşeanu, T. A., Camen, A., Popa, E. G., Rusu, G., Cristofor, I., et al. (2018) · InTech eBooks · doi:10.5772/intechopen.72003 · Cited by 2
Menezes, C. E. D. S., McIntyre, R. S., Filho, A. J. M. C., Vasconcelos, S. M. M., de Sousa, F. C. F., Quevedo, J., Hyphantis, T. N., Carvalho, A. F., & Macêdo, D. S. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.07.003 · Cited by 2
Self-citationGe, J., Wang, Q., Wang, S., Xiong, X., & Zhai, Y. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1662778 · Cited by 6
Vortioxetine: a comprehensive update on a new-generation antidepressant
Evren, C. (2021) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2021.00115 · Cited by 2
Murthy, N. V., Xu, R., Zhong, W., & Harvey, P. D. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.025 · Cited by 2
Jespersen, C. P., Pedersen, H. F., Kleinstäuber, M., Fink, P., Wellnitz, K. B., Ørnbøl, E., Schröder, A., Agger, J. L., Vase, L., Finnerup, N. B., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107524 · Cited by 2
Donegan, K. R., Hossein, S., Panny, B., Brown, V. M., Lee, C. T., Harty, S., Lynch, K., Fox, C. A., Hanlon, A. K., O’Keane, V., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03722-8 · Cited by 4
Nikolin, S., Tan, Y. Y., Martin, D. M., et al. (2020) · doi:10.31234/osf.io/h8dmr · Cited by 1
Metacognition in anxious-depression is state-dependent: an observational treatment study
Fox, C. A., Lee, C. T., Hanlon, A. K., Seow, T. X., Lynch, K., Harty, S., Richards, D., Palacios, J., O’Keane, V., Stephan, K. E., et al. (2023) · doi:10.7554/elife.87193.2 · Cited by 1
Role of the SARS-CoV-2 Virus in Brain Cells
Azargoonjahromi, A. (2024) · Viral Immunology · doi:10.1089/vim.2023.0116 · Cited by 2
Danilov, D. S. (2023) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202312301147 · Cited by 1
Dølven, S., Moroń, M., Eriksen, I., Toft, J. E. G., & Semkovska, M. (2025) · Neuropsychology Review · doi:10.1007/s11065-025-09686-2 · Cited by 2
Yang, K., Tiwari, S., Liu, D., Xu, Q., Qi, L., Zhu, Y. P., Jiang, L., Zouqin, H., Wong, J. W., Chen, J., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-091214 · Cited by 2
Zhu, X., Chen, X., Wu, Y., Feng, L., & Chen, X. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06538-4 · Cited by 4
Davis, M. P. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_81-1 · Cited by 1
Contemporary approaches to correction of cognitive impairment in endogenous depression
Oleichik, I. V., Shishkovskaia, T. I., & Баранов, П. А. (2020) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2020-4-82-93 · Cited by 1
Ren, F.-F., Chen, F., Zhou, W.-S., Guo, Y.-F., Dou, R.-R., Lin, Y.-X., Pan, X.-F., Wu, Y., Brazaitis, M., Liang, W.-M., et al. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117023 · Cited by 2
The Role Of Serotonin In The Cognitive Function Of The Elderly : A Literature Review
Pasaribu, R. H., Ichwan, M., Rambe, A. S., Malisie, R. F., & Widjaja, S. S. (2023) · International Journal of Ecophysiology · doi:10.32734/ijoep.v5i1.12313 · Cited by 1
Pereira, L. A. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.87.2018.tde-09022018-152247 · Cited by 1
Ketamine and Cognitive Function in Depression: Detrimental, Neutral, or Advantageous?
Goldberg, J. F. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21com14243 · Cited by 2
D’Alessandro, G., Sommerhoff, C., Bort, M., Prisco, M. D., Fico, G., Oliva, V., Elefante, C., Torrent, C., Amoretti, S., Solé, B., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116699 · Cited by 1
Tangen, Ä., Borg, J., Tiger, M., Varnäs, K., Sorjonen, K., Lindefors, N., Halldin, C., & Lundberg, J. (2017) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2017.06.001 · Cited by 1
Pan, Z. (2018) · TSpace (University of Toronto) · Cited by 1
An observational treatment study of metacognition in anxious-depression
Fox, C. A., Lee, C. T., Hanlon, A. K., Seow, T. X., Lynch, K., Harty, S., Richards, D., Palacios, J., O'Keane, V., Stephan, K. E., et al. (2023) · eLife · doi:10.7554/elife.87193.3 · Cited by 1
“However, studies examining the impact of antidepressants on cognition have typically focused on cognitive capacities other than metacognition (Prado et al., 2018; Rosenblat et al., 2015; Salagre et al., 2017; Vernon et al., 2014).”
BackgroundNeurobiological Aspects of Functional Recovery in Major Depressive Disorder
Chakrabarty, T., Sarfati, D., & Lam, R. W. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00024-x · Cited by 2
Is vortioxetine as preferable a molecule as duloxetine in depressed patients with fibromyalgia?
Aker, D. A., & Öke, D. (2025) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2025.09.004 · Cited by 1
DePamphilis, G., Legere, C. H., Vigne, M. M., Tirrell, E., Holler, K. A., Carpenter, L. L., & Kavanaugh, B. C. (2024) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acae103 · Cited by 1
Deardorff, W. J., & Grossberg, G. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-74604-3_9
Lustyk, K., Jagielska, A., Sałaciak, K., Dudzik, P., Soren, A., Konwar, J., Żelaszczyk, D., Marona, H., Crouzier, L., Meunier, J., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118454
Machado, L. D. (2017) · Juniper Online Journal of Case Studies · doi:10.19080/jojcs.2017.01.555566
Is anxiety a risk factor in cognitive ageing?
Arthur, R. (2019) · ANU Open Research (Australian National University) · doi:10.25911/5d5148b663c66
Berkovitch, L., Vinckier, F., Salvador, A., Pessiglione, M., Deakin, J. F. W., DAWSON, G. E., Harmer, C. J., Goodwin, G. M., & Gaillard, R. (2026) · medRxiv · doi:10.64898/2025.12.30.25342896
Machado, L. (2016) · Juniper Online Journal of Case Studies · doi:10.19080/jojcs.2016.01.555566
Kumar, A., Kumari, S., Verma, A. K., Kumar, A., & Pradhan, R. K. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i12.2458
Efectos del tratamiento antidepresivo en la cognición de pacientes con enfermedad de Alzheimer
García-Alberca, J. M. (2023) · Kranion · doi:10.24875/kranion.m23000048 · Cited by 1
Cognitive Dysfunction and Suicide
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_19
Liu, L., Li, P., Hu, Y., Shan, Q., Li, H., Wei, Y., & Wang, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-5371457/v1
The Approach to Diagnostic Ambiguity
Goldberg, J. F., & Stahl, S. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009181549.004
The relationship between cognition and the pharmacotherapy of depression
Ainsworth, N. J., & Mulsant, B. H. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2605201
Immunogenetic determinants of chemotherapy response in cancer
Vacchelli, E. (2014) · theses.fr (ABES) · doi:10.70675/45a5a056z4084z4e80z9c2czba2370caaa78
PET studies of the serotonin system in relation to behavioral phenotypes in psychiatry
Tangen, Ä. (2020) · Figshare
Zhao, M., & Liu, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-2321186/v1
Psychopharmacology of Depression
Pakdemir, S. D., & Güneş, M. (2024) · doi:10.69860/nobel.9786053359456.2
Soubata, H., Mazur-Lainé, E., Leclerc, J. B., Gauthier, B., Blanchet, P. J., O’Connor, K. P., & Lavoie, M. E. (2026) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2026.2681009
Pharmacological interventions for cognitive dysfunction
Baune, B. T. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198835554.003.0007
Research Progress of MECT and SSRIs on Cognitive Function of Depressive Disorder
吴, 潇. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151134
Metadata
- Authors
- Rosenblat, J. D., Kakar, R., & McIntyre, R. S.
- Affiliations
- Western University (CA)
- Corresponding author
- McIntyre, Roger S
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-25
- Volume
- 19
- Issue
- 2
- Pages
- pyv082
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4772818
- OpenAlex
- W2212064423
- Semantic Scholar
- af52beccf94ac5808c5f0857633e857371da9c0d
- Cited by
- 315
- References
- 32
- Citations by year
- 2026: 8 · 2025: 27 · 2024: 43 · 2023: 34 · 2022: 28 · 2021: 32 · 2020: 23 · 2019: 35 · 2018: 27 · 2017: 27 · 2016: 27 · 2015: 3
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- major depressive disorder, antidepressants, cognitive impairment, psychomotor speed, delayed recall, executive function, cognitive control, vortioxetine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants
- MeSH terms
- Antidepressive Agents, Cognition, Cognition Disorders, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.